1. A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants. (3rd October 2022) Authors: Perera, V; Abelian, G; Luettgen, J; Aronson, R; Li, D; Wang, Z; Zhang, L; Lubin, S; Merali, S; Murthy, B Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers. (25th November 2020) Authors: Perera, V; Wang, Z; Luettgen, J; Wang, J; Li, D; Desouza, M; Cerra, M; Seiffert, D Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗